Koninklijke Philips N.V. v. S.G.E.

OTEC Präzisionsfinish GmbHvsSTEROS GPA Innovative S.L.

This appeal concerned an application for provisional measures regarding alleged infringement of EP 4 249 647, which relates to an electrolytic medium and electropolishing process. The Court of Appeal set aside the first instance order that had granted an injunction against OTEC, finding that STEROS failed to demonstrate that the attacked embodiment (electropolishing medium EF 16-11) contained a non-conductive fluid with conductivity no greater than 10 micronS/cm as required by claim 1 of the patent. The Court held that experimental data not disclosed in the patent specification are generally not relevant to claim interpretation.

F. Hoffmann-La Roche AG a. o.vsA.Menarini Diagnostics S.r.l. a. o.

This case concerns an application for provisional measures (interim injunction) filed by F. Hoffmann-La Roche AG and Roche Diabetes Care GmbH against A.Menarini Diagnostics S.r.l., BERLIN-CHEMIE AG, and A.Menarini Diagnostics France SASU for alleged infringement of European Patent EP 1 962 668 B1. The Local Chamber Düsseldorf addressed key legal questions regarding the relevance of independent process claims and their descriptions when determining the scope of protection of independent product claims. The court also examined whether an injunction covering the making of a product can be issued when the infringing product has so far been manufactured by a third party outside the contracting member states.

Merz Pharmaceuticals LLC, Merz Therapeutics GmbH, Merz Pharma FrancevsViatris Santé

Merz, the proprietor of European Patent EP 2 377 536 and French Supplementary Protection Certificate No. 13C0033 covering FAMPYRA® (fampridine) for treating multiple sclerosis, sought provisional measures against Viatris Santé for marketing a generic version (FAMPRIDINE VIATRIS®) in France. The Paris Local Division rejected the application for lack of urgency, finding Merz had delayed unreasonably. The Court of Appeal set aside that order, granted the provisional measures, and ordered Viatris Santé to refrain from marketing the generic in France until the SPC expires on 25 July 2026.

Herbert Smith Freehills Kramer LLPvs1) Insulet Corporation; 2) EOFLOW Co., Ltd.

1 Milan - Central Division - First Instance - UPC_CFI_941/2025 Final Order pursuant to Rule 262.1 b) RoP of the Court of First Instance of the Unified Patent Court delivered on 16/10/2025 APPLICANT Herbert Smith Freehills Kramer LLP - Breite Str. 29, 40213 Düsseldorf, Germany Represent

Microsoft CorporationvsSuinno Mobile & AI Technologies Licensing Oy

Microsoft Corporation applied for an order treating certain information as strictly confidential in proceedings concerning European patent EP 2 671 173. The information in question consisted of invoices from Microsoft's law firm detailing hours spent on the case and fees agreed upon. The respondent objected, arguing no specific reason for confidentiality was provided and that cost specifications could not be considered trade secrets or attorney-client privileged. The Court granted Microsoft's application, holding that such information qualifies as confidential under Rule 262A RoP and falls within the scope of attorney-client privilege under Rule 287 RoP.